'Sakigake' Treatment Gives Enhertu Rapid Japan OK For Gastric Cancer

Zejula, Tecentriq Combo Also Cleared

Japan approves a batch of new products and indications, including Daiichi Sankyo's Enhertu in a high-need indication after a rapid review and Takeda's Zejula, which will be made available to selected patients before its reimbursement listing.

Japan_Approval
Japan Approves Multiple New Products • Source: Shutterstock

Daiichi Sankyo Co., Ltd.’s HER2-directed antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) has been approved in Japan, for the treatment of patients with HER2-positive unresectable advanced or recurrent gastric cancer that has progressed after chemotherapy.

The Japanese firm’s lead ADC asset, which links an HER2 antibody and topoisomerase I inhibitor payload, is already approved in...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Japan

More from Asia